Table 3.

Patient disposition: safety populationa

ParameterCohort 1/expansion (n = 31)Cohort 2a (n = 3)All patients (N = 34)
Discontinuation of treatment, n (%)31 (100)3 (100)34 (100)
Primary reasons for treatment discontinuation, n (%)
AE11 (35)0 (0)11 (32)
Disease progression7 (23)2 (67)9 (26)
Patient decision6 (19)1 (33)7 (21)
Investigator decision4 (13)0 (0)4 (12)
Initiation of subsequent therapy2 (6)0 (0)2 (6)
Sponsor decision1 (3)0 (0)1 (3)
  • aIncluded all patients who received at least 1 dose of pralatrexate or bexarotene.